Basic & Clinical Medicine ›› 2014, Vol. 34 ›› Issue (2): 270-273.

Previous Articles     Next Articles

Advances of HSP90 inhibitors in treating acute myelogenous leukemia


  • Received:2013-05-21 Revised:2013-06-20 Online:2014-02-05 Published:2014-01-13

Abstract: Heat shock protein 90 (HSP90) is a molecular chaperone with many oncogenic client which integrates multiple oncogenic pathways, involving the occurrence and poor prognosis in acute myelogenous leukemia (AML).Currently, HSP90 inhibitors are one research drugs of molecular targeted therapies in treating AML, via HSP90 inhibition to realize the regulation of multiple oncogenic pathways at the same time, and play a role of anti-leukemia effect.

Key words: Acute myelogenous leukemia, Heat shock protein 90 inhibitors, anti-leukemia, molecular target therapy